Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for chemotherapy-induced thrombocytopenia in gynecological cancers
ChiCTR2500102416Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Proportion of patients with platelet count recovery to ≥100 × 10^9/L and Treatment-related adverse events (TRAE). Planned start May 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2500102416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102416.